32 Biosciences Companies (Gateway Biome & Covira) offer Simple Agreement for Future Equity (SAFE) investment opportunities. The SAFE agreements for Gateway Biome and Covira terms $1.0M each for company, $0.1M minimum, 20% discount, Valuation Caps Gateway Biome $7.5M and Covira $22.5M. (Dec 2023)

32 Biosciences (Gateway Biome & Covira) signs a consulting agreement with Trusted Health Advisors (THA) and completes in-person kick-off meeting Nov 1-2 in Chicago. The THA collaboration will focus on Corporate Development & Financing and Development, Commercialization and Partnering Plan. (Nov 2023).

J Am Coll Surg. 2023 Oct 23 “Scientific Rationale Behind Intestinal Alkaline Phosphatase Administration to Enhance Recovery after Pancreaticoduodenectomy” John C Alverdy (Oct 2023)

32 Biosciences Companies (Gateway Biome & Covira) announce upcoming investment opportunities/capital raise offerings at The Chicago Family Office & High Net Worth Annual Conference. (Sept 2023)

Dis Colon Rectum. 2023 Sep 8 “Expert Commentary for Perioperative Malnutrition” John C Alverdy (Sept 2023)

Curr Opin Clin Nutr Metab Care. 2023 Sep 1 “The role of dietary prehabilitation on anastomotic healing” John C Alverdy (Sept 2023)

Covira submits nine grant applications in the first three quarters of 2023. Covira’s platform technology expansion strategy is to utilize non-dilutive grant funding awarded to establish proof of concept and develop incremental indications/assets. (Sept 2023)

Adv Surg. 2023 Sep “What Is the Role of the Gut in Wound Infections?” John C Alverdy, Et al (Sept 2023)

Science. 2023 Aug 4 “Peptide YY: A Paneth cell antimicrobial peptide that maintains Candida gut commensalism“ John C Alverdy, Et al (Aug 2023)

Covira signs agreement with Argonne National Laboratory to produce CS-0003 for pre-clinical (IND enabling) studies, and to develop a theoretical scalable manufacturing plan optimized for commercial quantities. During the initial academic study, Argonne collaborated in the development of CS-0003. Argonne has the infrastructure and expertise to replicate the initial synthesis and determine scalable manufacturing options. (July 2023)

Ann Surg. 2023 Jul 31 “Western Diet Induced Transcriptional Changes in Anastomotic Tissue is Associated with Early Local Recurrence in a Mouse Model of Colorectal Surgery” John C Alverdy, Et al (July 2023)

Ann Surg. 2023 Jul 19 “Studies Involving Surgical Site Infections (SSIs) without Culture Results, the Antibiotics Chosen for Prophylaxis and Antibiotic Sensitivity Data. "Are they actionable?"“ John C Alverdy (July 2023)

Am J Surg. 2023 Jul “Biologically inspired gastrointestinal stapler design: "Getting to Zero" complications” John C Alverdy (July 2023)

Covira hires two new employees Patrick Hennessey, Strategy and Business Development and Jeff McCown, Business Development. (June 2023)

Acad Med. 2023 Jun 1 “To Operate or Not? Balancing Advanced Imaging, Machine Learning, and the Doctor-Patient Relationship in Complex Clinical Decision Making” John C Alverdy, Et al (June 2023)

Covira hires new employee Kaitlyn Read, Product Development Scientist. (May 2023)

Surg Infect (Larchmt). 2023 Apr;24 “Rationale for Colonic Pre-Habilitation Prior to Restoration of Gastrointestinal Continuity” John C Alverdy (April 2023)

Polsky Center for Entrepreneurship and Education at The University of Chicago, 2023 Apr 12 “A Gut Check for Post-Op Infection: Covira Offers a Pro-Bacteria Approach”. (April 2023)

Anesthesiology. 2023 Apr 1 “Updates in Prevention of Surgical Site Infection: Reply” John C Alverdy, Et al (April 2023)

J Gastrointest Surg. 2023 Mar;27 “Pitfalls and Traps in the Surgical Evaluation of Patients with Irritable Bowel Syndrome (IBS)” John C Alverdy, Et al (Mar 2023)

Covira Announces Appointment of Brian Yoor as New Chairman of its Board of Directors. (Mar 2023)

Surg Infect (Larchmt). 2023 Feb;24 “"It Is Not Necessary to Kill Them in Order to Make Them Relatively Harmless": Molecular Diplomacy in the Pathogen-Host Interaction” John C Alverdy (Feb 2024)

Am J Surg. 2023 Feb 1 “Biologically inspired gastrointestinal stapler design: "Getting to Zero" complications” https://pubmed.ncbi.nlm.nih.gov/36775790/. (Feb 2023)

Clin Colon Rectal Surg. 2023 Jan 19 “The Role of the Gut Microbiome on the Development of Surgical Site Infections” John C Alverdy, Et al (Mar 2023)

Covira begins work to develop large animal pig model utilizing phase 1 funding from the NIH Seed Fund Fast Track Award. (Jan 2023)

Covira signs a consulting agreement with Eva Garland Consulting to initiate a project focused on successfully completing and submitting three non-dilutive grant opportunities per quarter. The strategic objective behind these incremental grant submissions is to harness the potential of Covira's platform technology and achieve proof of concept of its effectiveness in various indications. (Jan 2023).

Covira receive Notice of Award from NIH Seed Fund Fast Track Award ($299,066 upfront, with the potential for two large milestone payments). This non-dilutive grant funding is from the Department of Health and Human Services National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases. The Federal Award Project Title is “A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection.” *Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R42AI174369. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. (Dec 2022)

Surg Infect (Larchmt) 2022 Dec 15 "It Is Not Necessary to Kill Them in Order to Make Them Relatively Harmless": Molecular Diplomacy in the Pathogen-Host Interaction https://pubmed.ncbi.nlm.nih.gov/36521176/. (Dec 2022)

Covira receives a Notice of Allowance for the phosphorylated tri-block copolymer application (U.S. Patent Application No. 16/338,330) from the US Patent office. This is Covira’s second and the most important patent approval to date. (Nov 2022)

After a 7-month competitive process with over 4,000 companies, Covira is named 1 of 16 Most Fundable Companies, bringing home “gold” level recognition, Covira Named to the Pepperdine Graziadio Business School 2022 Most Fundable Companies List. (Oct 2022)

Pepperdine Graziadio Business School Announces the 2022 List of Most Fundable Companies More than 4,000 early-stage US companies across all 50 states participated in the Most Fundable Companies initiative. (Oct 2022)

Crain’s Chicago Business October, 7 2022; This UChicago spinout wants to change how we think about gut bacteria. (Oct 2022)

Covira’s first company issued press release Covira Builds Team, Closes First Dilutive Funding, Establishes Key Partnerships, and Prepares for Next Round of Funding. (Oct 2022)

Ann Surg. 2022 Sept 1 A Novel Non-Antibiotic Gut-Directed Strategy to Prevent Surgical Site Infections https://pubmed.ncbi.nlm.nih.gov/35749750/. (Sept 2022)

Covira expands Business Advisory Board, adding Julie Ferguson, Adjunct Professor at DePaul University College of Communications, and Healthcare Communications Consultant, Owner & Founder at JFPR Media Group. Julie will serve as Covira’s Head of Communications & Public Relations. (July 2022)

Covira selected as one of 100 semi-finalists chosen from over 4,000 participants nationwide in the 2022 Pepperdine Most Fundable Companies competition. (June 2022)

Covira completes nine-month program and graduates from Creative Destruction Lab (CDL) Program at CDL-Toronto as part of their Health Treatments Stream. CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. (June 2022)

Covira appoints former Abbott Laboratories Executive Vice President, Chief Financial Officer Brian Yoor to serve on Covira’s Board of Directors. Brian is currently the Chairman and Operating Partner at Portal Innovations. (May 2022)

Covira expands Business Advisory Board, adding Patrick Hennessey, MD, Due Diligence Director for the Keiretsu Forum Midwest and Chair of group’s Life Science Deal Screening Committee. (May 2022)

Covira exceeds 1H 2022 Goal to raise $1.0M, closing first dilutive funding via $1.0M Seed Round (oversubscribed). (April 2022)

Covira in the News “Going with a Gut Feeling” by Lake County Partners, Date: April 19, 2022. (April 2022)

Covira Signs Agreement with Contract Development Manufacturing Organization (CDMO) Bright Path Labs to Produce lead asset CS-0003. (April 2022)

Covira establishes an impressive Business Advisory Board, the first members include biotech industry leaders Jeff Schaffnit and Jason Slotnik. (April 2022)

Covira’s Founder & Chief Scientific Officer (Dr. John Alverdy) presents abstract titled "A Novel Non-Antibiotic Gut-Directed Strategy to Prevent Surgical Site Infections" at the American Surgical Association's 142nd Annual Meeting. (April 2022)

Covira submits $2.3M STTR Fast-Track application “A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection” to the NIH SEED Fund. (April 2022)

Covira closes more than $500,000 (50%) of their current $1.0M Seed Offering - this is Covira’s first dilutive funding effort and this offering is scheduled to close by April 27, 2022. (March 2022)

Covira establishes an impressive Scientific Advisory Board…members include Amelia Bartholomew, MD, MPH, FACS, Eugene Chang, MD, FACP, Neil Hyman, MD FACS, FASCRS, Eric Pamer, MD, FACP and Matthew Tirrell, PhD. (Feb-March 2022)

Covira appoints former Abbott Laboratories Executive Officer and Global Diversified Life Science Leader Jaime Contreras to serve on Covira’s Board of Directors. (Jan 2022)

Covira signs consulting agreement with Eva Garland Consulting and kicks-off project to complete NIH-SEED Fund application for STTR Fast-Track grant opportunity. (Jan 2022)

Covira closes $200,000 COVID-19 Economic Injury Disaster Loan from the US Small Business Administration, payments are deferred for the first 2 years. (Jan 2022)

Covira signs consulting agreement with Sharon Ayd of Advarra to serve as Covira’s Chief Regulatory Officer - Sharon is the Vice President of Advarra’s Regulatory Center of Excellence. (Dec 2021)

Covira Named by Business Worldwide Magazine Among Top 20 Most Innovative Companies to Watch, 2021. (Nov 2021)

Medscape 15 Nov 2021; Hospital Safety Grades Show Significant Variation https://www.medscape.com/viewarticle/962983?src=soc_lk_share "The Fall 2021 report was based on 22 measures, and marks the first-time inclusion of post-operative sepsis..."

Covira signs agreement with IQVIA Biotech and begins work to complete and file an Investigational New Drug (IND) application with the FDA. (Oct 2021)

Covira is selected into the Creative Destruction Lab (CDL) Program at CDL-Toronto as part of their Health Treatments Stream. CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. (Sept 2021)

Covira begins collaboration with a global medical technology leader to develop a large animal model. (Aug 2021)

Science 30 Jul 2021: Vol. 373, Issue 6554, pp. 471 The post-antibiotic era is here https://science.sciencemag.org/content/373/6554/471

Covira completes target discovery, lead compound identification, optimization, pre-clinical development and proves Pi-PEG’s ability to safely and effectively reduce the risk of Surgical Site Infections, Anastomotic Leak and Sepsis in small animal models. (2021)

Expertise in Anastomotic Leak: Worldwide - J Alverdy equates to the top-rated expert in Anastomotic Leak in the world during the years 2011-2021; https://expertscape.com/ex/anastomotic+leak/p/earth (2021)

Covira completes Fortune 100 Company Research & Development agreement (October 2020)

Covira works with IQVIA Biotech to identify top three prioritized indications (Surgical Site Infection, Anastomotic Leak, Sepsis), forecast peak year sales opportunity ($2.2B), and determine development time and costs to launch all three indications (April 2020)

COVID-19 (March 2020)

Covira hires Chief Executive Officer Peter Farmakis; https://www.linkedin.com/in/peterfarmakis/ (February 2020)

Covira signs a Research & Development agreement with a Fortune 100 Company (April 2019)

The University of Chicago and Covira file patent application for PCT/US19/28748 Materials and Methods of Using an Inhibitor of Plasminogen Activation to Treat Anastomotic Leak (File Date: April 23, 2019)

Covira works with the Pritzker School of Molecular Engineering and Argonne National Laboratory to finalize development and synthesize the proprietary Pi-PEG technology (March 2019)

Covira Surgical , Inc, a spinout from the University of Chicago, is established (September 2018)

Dr. Alverdy and The University of Chicago receive approval for U.S. Patent 9,937,199 Materials and Methods for Preventing and Treating Anastomotic Leaks (Issue Date: April 10, 2018)

Dr. Alverdy and The University of Chicago file patent application for US, EPO, China Phosphorylated tri-block copolymers with anti-microbial properties (File Date: Sept 29, 2017)